Tamir brings more than 20 years of experience in the medical technology sector, with a track record of translating strategic vision into measurable business outcomes. 

In his new role, Tamir will lead the development and execution of the company’s regional sales strategy, including go-to-market planning, distribution networks, strategic partnerships, and product launches tailored to local market needs.

While continuing to prioritize commercial growth in the United States, the company is building the regulatory, operational, and commercial infrastructure needed to enter international markets. 

Its EMEA strategy will build on the successful U.S. launch of the LIBERTY system, leveraging existing U.S. Food and Drug Administration clearance and the anticipated CE mark approval, expected by the end of 2026. 

The company views EMEA as a significant growth opportunity, noting that Europe alone accounts for approximately 2.3 million peripheral endovascular procedures—comparable to volumes in the U.S.

“Endovascular robotics is at an inflection point, and LIBERTY is leading that transformation,” said Tamir. “With over two decades of experience across the diagnostic, interventional, and robotics space, I’ve rarely seen a technology so well positioned: it’s FDA-cleared, already commercially launched, and now advancing toward CE mark approval.”"